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Abstract: The diagnosis of dementia with Lewy bodies (DLB) is difﬁ  cult if one relies solely 
on clinical features. Current International Consensus Criteria for DLB have high speciﬁ  city but 
a signiﬁ  cant percentage of patients might be misdiagnosed. Reasons for clinical uncertainty 
regard the presence of concomitant motor signs in patients with Alzheimer’s disease as well as 
the observation that cognitive abnormalities in DLB might develop with memory impairment 
without signiﬁ  cant parkinsonism. This has clinical relevance as DLB patients may be particularly 
sensitive to anti-psychotics and even the effectiveness of atypical neuroleptics such as quetiapine 
for the treatment of agitation and hallucinations has been questioned by double-blind, placebo-
controlled, randomized studies. By contrast, acetyl-cholinesterase inhibitors such as rivastigmine 
have shown beneﬁ  t not only on cognitive but also on psychiatric symptoms. Recent evidence 
shows that striatal dopamine transporter binding of 123I-ioﬂ  upane SPECT is reduced in DLB 
and this is consistent with a signiﬁ  cant loss of nigral dopamine neurons in this disorder. Several 
studies have demonstrated the diagnostic accuracy of 123I-ioﬂ  upane in the differential diagnosis 
of parkinsonism. Given the availability of SPECT, this investigation represents a useful marker 
to support clinical diagnosis and can help establishing appropriate treatment for this disorder.
Keywords: dementia with Lewy bodies, 123I-ioﬂ  upane-SPECT, dopamine transporter, parkin-
sonism, Alzheimer’s disease
Introduction
Clinical diagnosis of patients presenting with extrapyramidal features is often prob-
lematic as signs and symptoms suggestive of Parkinson’s disease may be present in 
several parkinsonian syndromes. The diagnostic algorithm can be even more complex 
if additional cognitive deﬁ  cits are present. These cases, particularly when dementia 
precedes parkinsonism, might be difﬁ  cult to ascertain and a differential diagnosis with 
Alzheimer’s disease (AD) should be considered. This has clinical consequences since 
treatment strategies differ among disorders with dementia. Neuroimaging is helpful 
particularly when demonstration of abnormalities in the dopamine system is required. 
Tracers binding to the dopamine transporter (DAT) in the striatum have now reached 
widespread application and can be used, in addition to neurological examination, in 
those patients presenting clinical uncertainty (Tolosa et al 2006). 
Clinical diagnostic issues in patients with dementia 
with Lewy bodies
Current International Consensus diagnostic criteria deﬁ  ne patients with Parkinson’s 
disease dementia (PDD) as those presenting with parkinsonism prior to the onset Neuropsychiatric Disease and Treatment 2007:3(3) 288
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of dementia, while if parkinsonism and dementia develop 
concurrently they are classiﬁ  ed as dementia with Lewy 
bodies (DLB) (McKeith et al 2005). However, data on neu-
ropathology of these disorders are scarce and inconclusive 
about the possibility of distinguishing between patients 
with and without dementia (Aarsland et al 2004). In PD, 
the Lewy bodies are found mainly in the substantia nigra 
and other brainstem nuclei such as the locus ceruleus and 
raphe, whereas in DLB Lewy bodies are also present in a 
number of neocortical and archicortical areas (Apaydin et 
al 2002). Overall the 1-year rule described in the McKeith 
criteria, where patients presenting with less than 1 year of 
parkinsonism prior to dementia are diagnosed with DLB 
and patients with a longer duration of parkinsonism before 
the onset of dementia are diagnosed with PDD, is still com-
monly used for clinical and research purposes. This has been 
further reafﬁ  rmed in a recent consensus article where it is 
concluded that the different course of cognitive and motor 
symptoms in PDD and DLB justify a distinction between 
the two disorders (Lippa et al 2007). However, the same 
authors suggested that for research purposes it is currently 
more convenient to use a “Lewy body disorder model” in 
view of the presence of abnormal alpha-synuclein inclusions 
in both diseases (Lippa et al 2007).
Clinically, patients with DLB develop postural instabil-
ity and gait difﬁ  culties more frequently than in PD without 
dementia (Burn et al 2003). The response to levodopa is 
often unsatisfactory, suggesting that many extrapyramidal 
symptoms may have non-dopaminergic origin. In a recent 
study in 14 DLB patients, acute levodopa challenge yielded a 
13.8% improvement in UPDRS-III compared with 23% and 
21% in PD patients with and without cognitive dysfunction 
(Molloy et al 2005).
The environment is further complicated by the fact that 
DLB patients might be difﬁ  cult to separate from AD patients. 
Concurrent senile plaques and neuroﬁ  brillary tangles are 
common in both PDD and DLB possibly contributing to 
cognitive decline in these disorders (Aarsland et al 2005a, b). 
Moreover, cholinergic dysfunction has been reported also in 
DLB patients, making the differential diagnosis challenging 
in some cases (Tiraboschi et al 2000).
Difﬁ  culties in the differential diagnosis between DLB 
and AD have been highlighted by many studies that have 
reassessed “in life” diagnosis of dementia at neuropathology. 
In a series of 10 patients with a diagnosis of DLB who came 
to autopsy this could be conﬁ  rmed only in 5. Of the ﬁ  ve 
misdiagnosed cases, 4 had AD and 1 progressive supra-
nuclear palsy. The misdiagnosed DLB cases who had AD 
presented in life with fewer hallucinations but interestingly an 
equal amount of spontaneous extrapyramidal signs, even in 
the absence of neuroleptic treatment, further highlighting the 
limit of current diagnostic criteria (Hohl et al 2000). Similar 
results were found in a later study aimed at determining what 
clinical features, among visual hallucinations, extrapyramidal 
signs, and visuospatial impairment, might best predict at 
early disease stage a diagnosis of DLB at neuropathology 
compared with AD. In a cohort of 23 pathologically proven 
DLB patients vs 94 AD the authors found that among several 
clinical variables, visual hallucination was the most speciﬁ  c 
to DLB and visuospatial impairment the most sensitive. The 
best model for differentiating DLB from AD did not include 
extrapyramidal symptoms (Tiraboschi et al 2006). In another 
cohort of 44 DLB patients identiﬁ  ed among 788 cases with 
parkinsonism archived at the Queen Square Brain Bank in 
London, frequency of visual hallucinations was 50% of PD, 
73% of DLB, and only 7% of non-degenerative parkinsonism. 
Visual hallucinations were associated with cognitive impair-
ment, autonomic dysfunction, and axial rigidity within the 
ﬁ  rst 2 years of disease (Williams and Lees 2005). This is in 
line with the observation that patients who at neuropathology 
present signiﬁ  cant Alzheimer abnormalities in addition to 
Lewy bodies have predominantly memory impairment in 
life (Merdes et al 2003).
Conversely, the frequency of motor signs in AD is often 
underestimated, as suggested by a recent prospective evalu-
ation of 474 AD patients for an average period of 13 years 
where motor signs were observed in 13% of patients at ﬁ  rst 
examination rising to 36% of patients at the end of the follow-
up period. The main symptoms contributing to worsening 
mobility were gait and bradykinesia which signiﬁ  cantly 
predicted institutionalization and mortality (Scarmeas et al 
2004; Scarmeas et al 2005).
In view of these difﬁ  culties the recently revised consensus 
criteria have suggested adding new features to improve DLB 
diagnosis. In particular, imaging of the dopamine system has 
been proposed as the main instrumental investigation to help 
in the differential diagnosis among disorders with dementia 
(McKeith et al 2005). 
Because DLB, unlike AD, is characterized by degenera-
tion of nigral dopaminergic neurons, in vivo demonstration of 
dopaminergic loss can be considered an accurate diagnostic 
marker (Walker et al 1999).
Dopamine transporter imaging
SPECT imaging tracers binding to the dopamine transport-
ers are sensitive tools aimed at demonstrating the presence Neuropsychiatric Disease and Treatment 2007:3(3) 289
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of dopamine nerve terminal loss in the striatum (Antonini 
and De Notaris 2004; Scherﬂ  er et al 2007). There are two 
radiopharmaceuticals available for SPECT imaging, [123I]β-
CIT or [123I]2β-carboxymethoxy-3β-(4-iodophenyl)tropane) 
and 123I-ioﬂ  upane or [123I]N-w-ﬂ  uoropropyl-2β-carbometh-
oxy-3β-(4-iodophenyl)nortropane.
123I-ioﬂ  upane is a radioligand that binds to the dopamine 
transporter located in the presynaptic membrane of dopamine 
nerve terminals. The main advantage of 123I-ioﬂ  upane is that 
a steady state allowing SPECT imaging is reached at 3 hours 
after a single bolus injection of the radioligand, compared 
with the 18–24 hours required for [123I]β-CIT. Therefore 
image acquisition can be completed the same day. 
123I-ioﬂ  upane has been studied in a large number of trials 
using SPECT to identify in vivo loss of dopamine transporters 
in the striatum, especially the putamen, in patients with 
pre-synaptic parkinsonism (Benamer et al 2000a; Booij 
et al 2001). A European study conducted in 158 patients 
with a clinical diagnosis of parkinsonism compared their 
123I-ioﬂ  upane SPECT imaging with the visual assessment of 
27 subjects affected by ET and 35 healthy volunteers. The 
“institutional read” was the primary end-point of the study: 
it consisted of the visual assessment of 123I-ioﬂ  upane SPECT 
striatal uptake, and was conducted on scans reconstructed 
with the highest resolution in each participating center by 
an investigator blinded to clinical data. The “consensus 
blinded” read was the secondary end-point of the study and 
was reconstructed with raw data performed in each center: 
the resultant images were randomly evaluated by a blinded 
read panel of neurologists until an agreement was reached.
Sensitivity for the clinical diagnosis of parkinsonism was 
97% and speciﬁ  city for ET was 100% for the institutional 
read, whereas sensitivity was 95% and speciﬁ  city 93% for 
the consensus blinded (Benamer et al 2000b).
There is good consistency between visual and semi-
quantitative assessment, making 123I-ioﬂ  upane imaging easy 
to use also in a clinical routine setting (Ottaviani et al 2006).
Because DLB, PD with dementia, and PD are characterized 
by involvement of dopamine nigral neurons, imaging of 
striatal DAT helps in identifying these patients. Degeneration 
might be more widespread in DLB and might also involve 
projections to the caudate nucleus possibly contributing 
to cognitive impairment (Figure 1) (Lucignani et al 2002; 
Walker et al 2004).
Conversely, AD patients generally show normal striatal 
DAT binding (Walker et al 2002), making this pattern a 
speciﬁ  c and helpful disease marker (Figure 1). In addition 
to changes in the dopamine system, additional cortical 
abnormalities have been described in DLB. More speciﬁ  cally, 
a pattern of reduced perfusion or metabolism in the occipital 
lobe may occur in DLB but this does not help in single case 
assessment. Reduced temporoparietal function is instead 
common to both AD and DLB (Mito et al 2005). Striatal 
dopamine D2 receptor binding of 123I-IBZM SPECT may also 
be reduced in DLB but the overlap with AD is considerable 
(Walker et al 1997).
The rate of decline of striatal dopamine loss in DLB is 
similar to that in PD and PD dementia (Colloby et al 2005). 
However in DLB, dementia severity and motor impairment 
correlated with striatal tracer decline, suggesting that dopa-
minergic loss plays an important role both in cognitive and 
motor features.
Additional conﬁ  rmation about the relevance of DAT 
imaging in the differential diagnosis between DLB from AD 
comes from a study that compared in-life diagnosis, imaging, 
and neuropathology in 14 demented patients (Costa et al 
2003). Seven patients had in-life abnormal DAT imaging 
and were diagnosed as DLB: 6 had their in-life diagnoses 
conﬁ  rmed at neuropathology, while 1 showed coexistent 
striatal vascular infarction. By contrast, the ﬁ  ve individuals 
with in-life diagnosis of DLB but normal striatal binding 
had a post-mortem diagnosis of AD. This study conﬁ  rms 
that imaging of the dopamine system helps in the diagnos-
tic work-up of DLB and further highlights the complexity 
of clinical examination in the differential diagnosis among 
disorders with dementia.
Finally, a recently published phase III study used 
123I-ioﬂ  upane SPECT to assess DAT binding in 326 patients 
with clinical diagnoses of probable or possible DLB vs 
non-DLB dementia. The authors found that abnormal uptake 
had a 77.7% probability for detecting DLB with a 90.4% 
speciﬁ  city to exclude other forms of dementia, mostly AD. 
Diagnosis of dementia was established on clinical criteria 
rather than neuropathology. The authors concluded that DAT 
imaging improves diagnostic accuracy of DLB, particularly 
in cases presenting clinical uncertainty (McKeith et al 
2007).
Relevance of a correct diagnosis for 
DLB treatment 
Treatment of DLB patients requires control of motor symp-
toms as well as cognitive dysfunction, including deﬁ  cits in 
attention, apathy, ﬂ  uctuating cognition, behavioral abnor-
malities, confusion, delusions, hallucinations, and psychosis. 
Psychiatric symptoms often need treatment with neuroleptics 
but this occasionally causes adverse events in these patients. Neuropsychiatric Disease and Treatment 2007:3(3) 290
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In a recent survey severe reactions to neuroleptics have been 
reported in 53% of DLB patients but not in AD (Aarsland et 
al 2005a, b). In the ﬁ  rst report on this topic, McKeith et al 
(1992) described severe adverse reaction to neuroleptics in 
13 of 20 neuropathologically conﬁ  rmed cases of DLB. These 
patients were exposed to phenothiazines or haloperidol and 
presented, in addition to worsening parkinsonism, confu-
sion, and agitation, and in 2 cases developed neuroleptic 
malignant-like syndrome.
There is agreement that clozapine and quetiapine should 
be preferred in the treatment of psychiatric symptoms in 
DLB (Klein et al 2003; Poewe 2005). The effectiveness of 
clozapine has been proven in a controlled trial in PD patients 
with hallucinations and does not interfere with cognitive 
function, except for sedation (Parkinson Study Group 1999). 
Quetiapine has similar properties to clozapine and can be 
used safely in these patients. A retrospective evaluation 
found complete or partial remission of psychosis with low 
doses in almost 90% of DLB patients (Fernandez et al 2002). 
Two recent double-blind, placebo-controlled, studies have 
challenged quetiapine’s beneﬁ  t on psychiatric symptoms in 
DLB, PDD, and PD patients (Kurlan et al 2007; Rabey et al 
2007). In both studies the authors found no improvement in 
agitation or psychosis in patients with dementia and parkin-
sonism even though motor symptoms were unaffected by 
quetiapine treatment.
By contrast treatment strategies in AD differ and neurolep-
tics with more potent anti-dopaminergic activity such as halo-
peridol or risperidone might help in the management of behav-
ioral symptoms (De Deyn et al 1999; Mayeux et al 1999).
Similarly to AD, recent studies have assessed the 
effectiveness and safety of acetyl-cholinesterase inhibitors, 
such as rivastigmine and donepezil in DLB. In a large, 
randomized, placebo-controlled trial, rivastigmine treatment 
signiﬁ  cantly improved cognitive scales as well as secondary 
measures on ﬂ  uency and attention (McKeith et al 2000). The 
Figure 1 The images depict striatal dopamine transporter binding of with 123I-ioﬂ  upane – SPECT in one patient with dementia with Lewy bodies (DLB) (right panel) and in 
one with Alzheimer’s disease (AD) (left panel). It can be appreciated that 123I-ioﬂ  upane uptake in the basal ganglia is normal in AD but markedly reduced in the DLB patient, 
consistent with signiﬁ  cant impairment of striatal dopamine nerve terminals.
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magnitude of improvement is possibly even greater than 
AD, and some authors have suggested this treatment also 
as ﬁ  rst-line management of psychiatric symptoms in DLB 
(McKeith et al 2004).
Additional studies have looked at the effect of rivastig-
mine in patients with PD and dementia and found similar 
results (Werber et al 2001; Emre et al 2004). Current evi-
dence favors further research on the use of rivastigmine and 
acetyl-cholinesterase inhibitors in general, for the treatment 
of hallucinations and psychiatric symptoms in PD with 
dementia (Reading et al 2001; Bullock et al 2002).
Conclusions
The differential diagnosis between DLB and AD is complex 
and neuropathology studies demonstrate a high rate of misdi-
agnosis. This has clinical consequences particularly in view of 
the risk of severe adverse reactions to antipsychotics as well 
as of the potential beneﬁ  t of acetyl-cholinesterase inhibitors 
such as rivastigmine on cognitive and psychiatric disturbances 
of DLB patients. Considering that in DLB there is signiﬁ  cant 
loss of nigral neurons, imaging of the dopamine system is an 
appropriate and effective biological marker for this disorder. 
123I-ioﬂ  upane is a SPECT tracer that is now commonly used 
in clinical routine for the differential diagnosis between PD 
and ET because of its high speciﬁ  city and sensitivity. Recent 
studies in DLB have shown that imaging with 123I-ioﬂ  upane 
helps in identifying these patients and this is consistent with 
post-mortem assessment. Overall, current evidence favors the 
use of this imaging test in the diagnostic work-up of DLB.
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